Atara Biotherapeutics Inc Logo Image

Atara Biotherapeutics Inc

Atara Biotherapeutics Inc Banner Image

Most Recent Annual Report

2017 Annual Report and Form 10K

Atara Biotherapeutics Inc

Atara Biotherapeutics Inc does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.

Archived Annual Reports

  • Atara Biotherapeutics Inc
  • Atara Biotherapeutics Inc
  • Atara Biotherapeutics Inc

About Atara Biotherapeutics Inc

201-500 Employees
Based in South San Francisco, California

Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s most advanced T-cell immunotherapy in development, tabelecleucel or tab-cel™ (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+ PTLD), as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma (NPC). Atara is also developing off-the-shelf, allogeneic ATA188 and autologous ATA190 T-cell immunotherapies using a complementary targeted antigen recognition technology for specific EBV antigens believed to be important for the potential treatment of multiple sclerosis (MS). Atara's clinical pipeline also includes ATA520 targeting Wilms Tumor 1, or WT1, and ATA230 directed against cytomegalovirus, or CMV. The company was founded in 2012 and is headquartered in South San Francisco, California.

Ticker:
ATRA
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol